Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Mevidalen with Fluconazole in Healthy Subjects
NCT03942029Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mevidalen in Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) (8 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered Related to Study Drug at 11 weeks. Started Jun 2019; status: completed.
02
Drugs
mevidalen
03
Conditions
Parkinson's disease dementia (PDD)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT03942029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03942029.